Malaria: Confronting Challenges From Drug Discovery to Treatment

疟疾：面临从药物发现到治疗的挑战

• 批准号: 10468493
• 负责人: Thale Cross Jarvis
• 金额: $ 0.5万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-04 至 2023-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10468493
• 关键词: Academia; Address; Anti-malarial drug resistance; Antimalarials; Applied Research; Artemisinins; Basic Science; Bioinformatics; Biological Assay; Cessation of life; Clinical; Clinical Research; Collaborations; Colorado; Combined Modality Therapy; Communities; Country; Development; Drug Combinations; Drug resistance; Educational workshop; Epidemiology; Feedback; Genes; Genome; Health; Human; Industry; Knowledge; Learning; Malaria; Medicine; Mentors; Methodology; Modeling; Outcome; Parasites; Participant; Pharmaceutical Preparations; Phenotype; Plasmodium falciparum; Prophylactic treatment; Research; Research Personnel; Resistance; Scientific Advances and Accomplishments; Scientist; Technology; Testing; Therapeutic; Thinking; Treatment Efficacy; Update; base; burden of illness; career; clinical practice; data exchange; design; drug development; drug discovery; environmental enrichment for laboratory animals; improved; innovation; posters; pre-clinical; programs; research and development; resistance mechanism; symposium; therapy resistant; transmission process

ABSTRACT Support is requested for a Keystone Symposia conference entitled Malaria: Confronting Challenges From Drug Discovery to Treatment, organized by Drs. David Fidock, Kelly Chibale and Elizabeth Ashley. The conference will be held in Breckenridge, Colorado from April 10-13, 2022. This Keystone Symposia conference addresses the pressing need to accelerate the development of new antimalarials that can treat Plasmodium falciparum parasites, which have acquired resistance to existing first- line drugs. The conference is designed to review the recent innovations in antimalarial drug discovery, as well as examine preclinical and clinical models to test compounds in development. The program will explore the efficacy of artemisinin-based combination therapy (ACT) across different endemic settings and discuss current approaches to reducing the disease burden. Other topics that will be covered include a review of the current status of antimalarial resistance, including mechanistic studies and how they inform our understanding of drug modes of action. Finally, there will be discussions on new medicines, prophylaxis, treatment, and transmission- blocking strategies. This conference will bring together experts in drug discovery and development, mechanistic studies into drug modes of action and mechanisms of resistance, and field-based clinician-investigators and modelers to update attendees on the multiple aspects required to proceed from drug discovery through to development. Participants will learn about the current status of ACT efficacy in the field and how to respond to challenges posed by the emergence of antimalarial resistance. This forum will allow scientists in basic or applied research to exchange knowledge and ideas with field-based researchers and clinicians. There is no other forum which addresses this niche in such a concentrated program. Finally, the opportunity for networking at this conference is invaluable to the field at this point. It is anticipated that participants will develop new collaborations that will help drive the field forward and overcome this battle of resistance to current malaria therapeutics.

摘要 请求为题为“疟疾：面对毒品和犯罪问题的挑战”的Keystone专题讨论会会议提供支助。 发现治疗，由大卫菲多克博士，凯利奇巴莱和伊丽莎白阿什利。会议 将于2022年4月10日至13日在科罗拉多州布雷肯里奇举行。 本次Keystone研讨会会议解决了加快开发新能源的迫切需要， 抗疟药可以治疗恶性疟原虫寄生虫，这些寄生虫对现有的第一- 毒品这次会议的目的是审查最近的创新，在抗疟疾药物的发现，以及 作为检查临床前和临床模型，以测试开发中的化合物。该计划将探讨 青蒿素为基础的联合疗法（ACT）在不同地方病环境中的疗效，并讨论目前 减少疾病负担的方法。将涵盖的其他主题包括对当前 抗疟药耐药性的现状，包括机制研究及其如何为我们了解药物 行动方式。最后，将讨论新药、预防、治疗和传播- 封锁战略。 本次会议将汇集药物发现和开发，药物机制研究， 作用方式和耐药机制，以及实地的临床医生-调查人员和建模人员，以更新 从药物发现到开发所需的多个方面的与会者。 参与者将了解ACT在该领域的功效现状以及如何应对挑战 这是由抗疟药耐药性的出现引起的。这个论坛将允许科学家在基础或应用研究 与实地研究人员和临床医生交流知识和想法。没有其他论坛， 在这样一个集中的项目中解决了这个问题。最后，在这次会议上建立联系的机会 在这一点上是无价的。预计参与者将开展新的合作， 帮助推动这一领域的发展，克服对当前疟疾疗法的抗药性。